Literature DB >> 15737887

New insights into iron homeostasis through the study of non-HFE hereditary haemochromatosis.

Antonella Roetto1, Clara Camaschella.   

Abstract

Non-HFE haemochromatosis is a negative definition applied to all those haemochromatosis disorders that are unrelated to HFE mutations. Four genes are responsible for the distinct types of non-HFE haemochromatosis: hepcidin and hemojuvelin are the genes involved in type 2 or juvenile haemochromatosis, transferrin receptor 2 is involved in type 3 haemochromatosis, and ferroportin 1 is mutated in type 4, the atypical dominant form of primary iron overload. Molecular genetic studies of these conditions have greatly contributed to our understanding of the regulation of iron absorption. A milestone was the discovery that hepcidin, the key iron regulator in mice, is the gene mutated in the most severe, juvenile form of haemochromatosis. This finding indicates a fundamental role of hepcidin in inhibiting both iron absorption from duodenal cells and iron release from macrophages, and has opened up a new view of haemochromatosis as a disorder of hepcidin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15737887     DOI: 10.1016/j.beha.2004.09.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  12 in total

Review 1.  Iron overload due to mutations in ferroportin.

Authors:  Ivana De Domenico; Diane McVey Ward; Giovanni Musci; Jerry Kaplan
Journal:  Haematologica       Date:  2006-01       Impact factor: 9.941

2.  Down-regulation of hepcidin in porphyria cutanea tarda.

Authors:  Richard S Ajioka; John D Phillips; Robert B Weiss; Diane M Dunn; Maria W Smit; Sean C Proll; Michael G Katze; James P Kushner
Journal:  Blood       Date:  2008-09-22       Impact factor: 22.113

3.  Guest editorial: the seven wonders of erythropoiesis.

Authors:  Kenichi Sawada
Journal:  Int J Hematol       Date:  2011-01-12       Impact factor: 2.490

4.  Convergence of hepcidin deficiency, systemic iron overloading, heme accumulation, and REV-ERBα/β activation in aryl hydrocarbon receptor-elicited hepatotoxicity.

Authors:  Kelly A Fader; Rance Nault; Mathew P Kirby; Gena Markous; Jason Matthews; Timothy R Zacharewski
Journal:  Toxicol Appl Pharmacol       Date:  2017-02-16       Impact factor: 4.219

5.  The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study.

Authors:  Elizabeta Nemeth; Gloria C Preza; Chun-Ling Jung; Jerry Kaplan; Alan J Waring; Tomas Ganz
Journal:  Blood       Date:  2005-09-01       Impact factor: 22.113

6.  Of mice and men: the iron age.

Authors:  Sophie Vaulont; Dan-Qing Lou; Lydie Viatte; Axel Kahn
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

7.  A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis.

Authors:  Marie-Laure Island; Anne-Marie Jouanolle; Annick Mosser; Yves Deugnier; Véronique David; Pierre Brissot; Olivier Loréal
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

8.  Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents.

Authors:  Etheresia Pretorius; Janette Bester; Natasha Vermeulen; Boguslaw Lipinski; George S Gericke; Douglas B Kell
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

9.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

10.  Increased Retinal Expression of the Pro-Angiogenic Receptor GPR91 via BMP6 in a Mouse Model of Juvenile Hemochromatosis.

Authors:  Pachiappan Arjunan; Jaya P Gnanaprakasam; Sudha Ananth; Michelle A Romej; Veeranan-Karmegam Rajalakshmi; Puttur D Prasad; Pamela M Martin; Mariappan Gurusamy; Muthusamy Thangaraju; Yangzom D Bhutia; Vadivel Ganapathy
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-04       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.